Chemotherapy and chemoembolization of patients with oncopathology as a risk factor for the development of myocardial dysfunction

Saule Kubekova 1 * , Natalya Zagorulya 1, Yelena Ryb 2, Niyaz Malayev 3, Aruzhan Abdilda 1
More Detail
1 Department of Cardiology, Astana Medical University, Astana, Kazakhstan
2 Department of Internal Medicine with a Course of Gastroenterology, Endocrinology and Pulmonology, Astana Medical University, Astana, Kazakhstan
3 Department of General and Thoracic Surgery, National Scientific Medical Center, Astana, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 20, Issue 2, pp. 4-8. https://doi.org/10.23950/jcmk/13122
OPEN ACCESS 897 Views 609 Downloads
Download Full Text (PDF)

ABSTRACT

Considering the aging of the population, the combination of cardiovascular diseases with oncopathology is gaining more relevance. Liver cancer occupies the 6th place in the structure of the incidence of neoplasms and the 3rd place in mortality from all oncological diseases. One of the main methods of treating patients with liver cancer is chemotherapy and chemoembolization, which significantly affect the myocardium, developing cardiotoxicity. Myocardial damage is reflected in the development of heart failure, which subsequently is the main cause of death in cancer patients.
Keywords: liver cancer, cardiotoxicity, chemoembolization, treatment, heart failure

CITATION

Kubekova S, Zagorulya N, Ryb Y, Malayev N, Abdilda A. Chemotherapy and chemoembolization of patients with oncopathology as a risk factor for the development of myocardial dysfunction. J CLIN MED KAZ. 2023;20(2):4-8. https://doi.org/10.23950/jcmk/13122

REFERENCES

  • https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf
  • https://www.who.int/ru/news-room/fact-sheets/detail/cancer
  • https://www.who.int/publications/m/item/cancer-kaz-2020
  • Siegel RL, Miller KD, Jemel A. Cancer statistics 2018. CA: Cancer J Clin. 2018;68:7-30. https://doi.org/10.3322/caac.21442
  • Skitch A, Mital S, Mertens L, et al. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study. BMC Cancer. 2017;17:519. https://doi.org/10.1186/s12885-017-3505-0
  • Zheng HC, Onderko L, Francis SA.Cardiovascular Risk in Survivors of Cancer. Curr Cardiol Rep. 2017;19:64. https://doi.org/10.1007/s11886-017-0873-7
  • https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
  • Zdorov'e naselenija Respubliki Kazahstan i dejatel'nost' organizacii zdravoohranenija v 2001-2020 g.g.», Stat. sborniki.-Astana,Almaty, Nur-Sultan.-2002-2021.
  • Ar'eva G.T., Sovetkina N.V., Ovsjannikova N.A. i dr. Komorbidnye i mul'timorbidnye sostojanija v geriartrii (obzor). Uspehi gerontologii. 2011; 24 (4):612.
  • Vertkin A.L., Skotnikov A.S. Komorbidnost'. Lech. Vrach. 2013; 6: 66–69.
  • Kejt Nadal' 'Ginard. Kogda odno meshaet drugomu – komorbidnost' na zlobe dnja. Novaja medicina tysjacheletija. 2012; 6: 22–24.
  • Marti S. Body weight and comorbidity predict mortality in COPD patients treated with оxygen therapy. Eur. Respir. J. 2006; 27(4):689–696. https://doi.org/10.1183/09031936.06.00076405
  • Kholodenko B.N., Bruggeman F.J., Sauro H.M. Mechanistic and modular approaches to modeling and inference of cellular regulatory netwoks. Systems biology: Definitions and perspectives. Springler–Verlag. 2007; 143–159. https://doi.org/10.15789/1563-0625-PEO-2222
  • Memorandum ESC po lecheniju onkologicheskih zabolevanij i serdechno-sosudistoj toksichnosti razrabotannyj pod jegidoj komiteta po praktike ESC 2016, podgotovlennoj Rabochej gruppoj po onkologicheskim zabolevanijam i serdechno-sosudistoj toksichnosti Evropejskogo obshhestva kardiologov (EOK). https://doi.org/10.15829/1560-4071-2017-3-105-139
  • Chazova I.E., S.A.Tjuljandin S.A., Vicenja M.V. i soavt. Rukovodstvo po diagnostike, profilaktike i lecheniju serdechno-sosudistyh oslozhnenij protivoopuholevoj terapii. Rossijskij kardiologicheskij zhurnal. 2017; 3(143). https://doi.org/10.26442/2075-082X_14.3.6-20
  • Vicenja M. V. i soavt. Prakticheskie rekomendacii po korrekcii kardiovaskuljarnoj toksichnosti protivoopuholevoj lekarstvennoj terapii. Zlokachestvennye opuholi: Prakticheskie rekomendacii RUSSCO. 2018; 8: 545–563. https://doi.org/10.18027/2224-5057-2021-11-3s2-41
  • Gilchrist, S. C. et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation. 2019; 139: e997–e1012. https://doi.org/10.1161/CIR.0000000000000679
  • Kelsey C. Stoltzfus, Ying Zhang, Kathleen Sturgeon et al. Fatal heart disease among cancer patients. Nature Communications. 2020; 2011:2020. https://doi.org/10.1038/s41467-020-15639-5
  • G. Curigliano, D. Cardinale, S. Dent, C. Criscitielloetal. CipollaCardiotoxicity of anticancer treatments: epidemiology, detection, and management. GA A Cancer J. Clin. 2016; 66:309-325. https://doi.org/10.3322/caac.21341
  • Global Burden of Disease Cancer, C. Fitzmaurice, T.F. Akinyemiju et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018; 4:1553-1568. https://doi.org/10.1001/jamaoncol.2018.2706
  • Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014; 89(9):1287-306. https://doi.org/10.1016/j.mayocp.2014.05.013
  • Chen Z.I., Ai D.I. Cardiotoxicity associated with targeted cancer therapies. Mol. Clin. Oncol. 2016; 4: 675–681. https://doi.org/10.3892/mco.2016.800
  • Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006;33 (1):2–14. https://doi.org/.1053/j.seminoncol.2005.11.001
  • M.S. Ewer, S.M. Ewer. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. 2010; 7: 564-575. https://doi.org/10.1038/nrcardio.2010.121
  • Seliverstova D.V., Evsina O.V. Kardiotoksichnost' himioterapii. Serdce: zhurnal dlja praktikujushhih vrachej. 2016;15 (1): 50-57. https://doi.org/10.18087/rhj.2016.1.2115
  • Vasjuk Ju.A., Shkol'nik E.L., Nesvetov V.V. i dr. Kardioonkologija: sovremennye aspekty profilaktiki antraciklinovoj kardiotoksichnosti. Kardiologija. 2016;56(12):72-79. https://doi.org/10.18565/cardio.2016.12.72-79
  • Bellinger, A. M. et al. Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation. 2015; 132:2248–2258. https://doi.org/10.1161/CIRCULATIONAHA.115.010484
  • Felker G.M.,ThompsonR.E., HareJ.M.et al. Underlyingcausesandlong-term survival in patients with initially unexplained cardiomyopathy. NEnglJMed. 2000;342(15):1077-1084. https://doi.org/10.1056/NEJM200004133421502
  • BovelliD.,PlataniotisG.,RoilaF. Cardiotoxicityof chemotherapeutic agents and radiotherapy - related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21 (5):277-582. https://doi.org/10.1093/annonc/mdq200
  • Bonow R. O., Bennett S., Casey D. E. et al. ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America. Circulation. 2005; 112(12):1853-1887. https://doi.org/10.1161/CIRCULATIONAHA.105.170072
  • Hooning MJ, Botma A, Aleman BM, Baaijens MH et al. Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007; 99: 365–375. https://doi.org/10.1093/jnci/djk064
  • Chow EJ, Mueller BA, Baker KS et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med. 2011; 155: 21–32. https://doi.org/10.7326/0003-4819-155-1-201107050-00004
  • Baker KS, Ness KK, Steinberger J, Carter A, Francisco L, Burns LJ, Sklar C, Forman S, Weisdorf D, Gurney JG, Bhatia S. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplantation Survivor Study. Blood. 2007; 109:1765–1772. https://doi.org/10.1182/blood-2006-05-022335
  • Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am CollCardiol. 2007; 50:1435–1441. https://doi.org/10.1016/j.jacc.2007.06.037
  • Koelwyn GJ, Khouri M, Mackey JR, Douglas PS, Jones LW. Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship. JClinOncol. 2012; 30:4458–4461. https://doi.org/10.1200/JCO.2012.44.0891
  • Chang J., Rattner D. W. History of minimally invasive surgical oncology. Surgical Oncology Clinics of North America. 2019; 28: 1–9. https://doi.org/10.1016/j.soc.2018.07.001
  • Weng L, Akurati S, Donelson RB et al. In vitro evaluation of sunitinib loaded bioresorbable microspheres for potential application in arterial chemoembolization. Colloids Surf B Biointerfaces. 2017; 159: 705-711. https://doi.org/10.1016/j.colsurfb.2017.08.038
  • Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86. https://doi.org/10.1002/ijc.29210
  • Jiang L, Lei JY, Wang WT, Yan LN, Li B, Wen TF, et al. Immediate radical therapy or conservative treatments when meeting the milan criteria for advanced HCC patients after successful TACE. J Gastrointest Surg. 2014;18(6):1125–30. https://doi.org/10.1007/s11605-014-2508-2
  • Yammasaki T, Hamabe S, Saeki I, Harima Y, Yamaguchi Y, Uchida K, et al. A novel transarterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol. 2011;46:359–66. https://doi.org/10.1007/s00535-010-0306-5
  • Singal AG, Zhang P, Waljee AK, Ananthakrishnan L, Parikh ND, Sharma P, et al. Body composition features predict overall survival in patients with hepatocellular carcinoma. Clin Trans Gastroenterol. 2016;26(7):e172. https://doi.org/10.1038/ctg.2016.31
  • Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019
  • Bolondi L, Burroughs A, Dufour J-F, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. In: Seminars in Liver Disease. Thieme Medical Publishers. 2012; 348–359. https://doi.org/10.1055/s-0032-1329906
  • Grandhi MS, Kim AK et al. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016; 25: 74–85. https://doi.org/10.1016/j.suronc.2016.03.002
  • Sperker B, Mürdter TE, Schick M, Eckhardt K, Bosslet K, Kroemer HK. Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney: consequences for drug metabolism. J Pharmacol Exp Ther. 1997;281(2):914-20.
  • Llovet JM, Real MI, Montanya X, Planas R, Coll S, Aponte J,et al. Arterial embolization, chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002; 359:1734–9. https://doi.org/10.1016/S0140-6736(02)08649-X
  • Tsurusaki M, Murakami T. Surgical and locoregional therapy of HCC: TACE. Liver Cancer. 2015;4(3):165–75. https://doi.org/10.1159/000367739
  • Coleman M.P., Forman D., Bryant H., Butler J., Rachet B., Maringe C. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377:127–138. https://doi.org/10.1016/S0140-6736(10)62231-3
  • Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T. Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial. Cardiology. 2012; 123:240–247. https://doi.org/10.1159/000343622
  • Villani F, Meazza R, Materazzo C. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography. Anticancer Res. 2006;26(1B):797-801.